Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral decitabine/cedazuridine plus ivosidenib for newly diagnosed IDH1-mutated acute myeloid leukemia in older or intensive-chemotherapy-ineligible adults
2025-523238-17-00Phase 2Authorised
- Sponsor
- PETHEMA
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of decitabine and ivosidenib in acute myeloid leukemia (AML), sponsored by PETHEMA. Primary endpoints: Complete response/immunophenotypic complete response and Safety. Planned start Jun 2026; status: authorised.
02
Drugs
decitabineivosidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2025-523238-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523238-17-00.